Susquehanna International Group’s Kymera Therapeutics KYMR Stock Holding History

Susquehanna International Group’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.46M	Buy	73,800 +29,700	+67%	+$2.55M	﹤0.01%	3660
2026 Q1	$3.67M	Sell	44,100 -10,800	-20%	-$855K	﹤0.01%	4836
2025 Q4	$4.27M	Buy	54,900 +16,600	+43%	+$1.12M	﹤0.01%	4272
2025 Q3	$2.17M	Buy	38,300 +23,400	+157%	+$1.06M	﹤0.01%	5600
2025 Q2	$650K	Buy	14,900 +7,400	+99%	+$255K	﹤0.01%	8554
2025 Q1	$205K	Buy	7,500 +1,900	+34%	+$69.3K	﹤0.01%	10880
2024 Q4	$225K	Sell	5,600 -11,800	-68%	-$533K	﹤0.01%	10458
2024 Q3	$824K	Buy	+17,400	New	+$768K	﹤0.01%	7277
2023 Q3	–	Sell	-16,500	Closed	-$379K	–	12520
2023 Q2	$379K	Sell	16,500 -2,300	-12%	-$65.9K	﹤0.01%	8956
2023 Q1	$557K	Buy	+18,800	New	+$606K	﹤0.01%	8300
2022 Q4	–	Sell	-10,500	Closed	-$229K	–	13099
2022 Q3	$229K	Buy	+10,500	New	+$277K	﹤0.01%	10493

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Susquehanna International Group's KYMR Position: Q2 2026 in Review

Susquehanna International Group reduced its Kymera Therapeutics (KYMR) stake by 80% in Q2 2026, selling an estimated $1.75M and leaving 5,061 shares worth $580K. The position accounts for ﹤0.01% of the portfolio, ranked #9563.

Susquehanna International Group first reported a position in KYMR in Q1 2021 and has held it in 21 quarters since. The position peaked at $2.51M in Q2 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Susquehanna International Group held 5,061 shares of Kymera Therapeutics worth $580K as of Q2 2026.
Susquehanna International Group sold 20,342 Kymera Therapeutics shares in Q2 2026, an estimated $1.75M.
Kymera Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #9563 holding.
Susquehanna International Group first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 21 quarters since.
Susquehanna International Group's Kymera Therapeutics position peaked at $2.51M in Q2 2025.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.